Overview
The marketing authorisation for Altargo has been withdrawn at the request of the marketing authorisation holder.
Altargo : EPAR - Summary for the public
English (EN) (472.97 KB - PDF)
български (BG) (1.12 MB - PDF)
español (ES) (505.45 KB - PDF)
čeština (CS) (650.52 KB - PDF)
dansk (DA) (504.78 KB - PDF)
Deutsch (DE) (506.21 KB - PDF)
eesti keel (ET) (504.17 KB - PDF)
ελληνικά (EL) (676.26 KB - PDF)
français (FR) (506.58 KB - PDF)
italiano (IT) (505.1 KB - PDF)
latviešu valoda (LV) (651.97 KB - PDF)
lietuvių kalba (LT) (619.1 KB - PDF)
magyar (HU) (639.94 KB - PDF)
Malti (MT) (650.13 KB - PDF)
Nederlands (NL) (505.72 KB - PDF)
polski (PL) (654.82 KB - PDF)
português (PT) (505.57 KB - PDF)
română (RO) (614.22 KB - PDF)
slovenčina (SK) (644.28 KB - PDF)
slovenščina (SL) (635.63 KB - PDF)
Suomi (FI) (504.95 KB - PDF)
svenska (SV) (504.61 KB - PDF)
Product information
Altargo : EPAR - Product Information
English (EN) (799.43 KB - PDF)
български (BG) (1.42 MB - PDF)
español (ES) (812.94 KB - PDF)
čeština (CS) (1.28 MB - PDF)
dansk (DA) (815.41 KB - PDF)
Deutsch (DE) (809.14 KB - PDF)
eesti keel (ET) (750.21 KB - PDF)
ελληνικά (EL) (1.46 MB - PDF)
français (FR) (815.25 KB - PDF)
hrvatski (HR) (874.78 KB - PDF)
íslenska (IS) (794.04 KB - PDF)
italiano (IT) (800.77 KB - PDF)
latviešu valoda (LV) (1.23 MB - PDF)
lietuvių kalba (LT) (851.86 KB - PDF)
magyar (HU) (1.23 MB - PDF)
Malti (MT) (1.24 MB - PDF)
Nederlands (NL) (813.69 KB - PDF)
norsk (NO) (805.77 KB - PDF)
polski (PL) (1.2 MB - PDF)
português (PT) (846.48 KB - PDF)
română (RO) (881.66 KB - PDF)
slovenčina (SK) (1.22 MB - PDF)
slovenščina (SL) (1.18 MB - PDF)
Suomi (FI) (806.83 KB - PDF)
svenska (SV) (780.46 KB - PDF)
Latest procedure affecting product information: N/0030
09/11/2015
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Altargo : EPAR - All Authorised presentations
English (EN) (464.31 KB - PDF)
български (BG) (550.48 KB - PDF)
español (ES) (468.17 KB - PDF)
čeština (CS) (543.17 KB - PDF)
dansk (DA) (463.61 KB - PDF)
Deutsch (DE) (463.97 KB - PDF)
eesti keel (ET) (464.73 KB - PDF)
ελληνικά (EL) (542.82 KB - PDF)
français (FR) (464.58 KB - PDF)
italiano (IT) (463.94 KB - PDF)
latviešu valoda (LV) (543.45 KB - PDF)
lietuvių kalba (LT) (528.34 KB - PDF)
magyar (HU) (541.04 KB - PDF)
Malti (MT) (541.98 KB - PDF)
Nederlands (NL) (464.13 KB - PDF)
polski (PL) (544.12 KB - PDF)
português (PT) (464.65 KB - PDF)
română (RO) (524.19 KB - PDF)
slovenčina (SK) (543.19 KB - PDF)
slovenščina (SL) (509.38 KB - PDF)
Suomi (FI) (463.61 KB - PDF)
svenska (SV) (464.71 KB - PDF)
Product details
- Name of medicine
- Altargo
- Active substance
- retapamulin
- International non-proprietary name (INN) or common name
- retapamulin
- Therapeutic area (MeSH)
- Impetigo
- Staphylococcal Skin Infections
- Anatomical therapeutic chemical (ATC) code
- D06AX13
Pharmacotherapeutic group
Antibiotics and chemotherapeutics for dermatological useTherapeutic indication
Short term treatment of the following superficial skin infections:
- impetigo;
- infected small lacerations, abrasions or sutured wounds.
See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Authorisation details
- EMA product number
- EMEA/H/C/000757
- Marketing authorisation holder
- Glaxo Group Ltd
980 Great West Road
Brentford
Middlesex TW8 9GS
United Kingdom - Marketing authorisation issued
- 24/05/2007
- Revision
- 15
Assessment history
Altargo : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (627.01 KB - PDF)
Altargo-H-C-757-P46-017.1 : EPAR - Assessment Report
English (EN) (681.15 KB - PDF)
Altargo-H-C-757-P46-0017 : EPAR - Assessment Report
English (EN) (684.34 KB - PDF)
More information on Altargo
Public statement on Altargo: Withdrawal of the marketing authorisation in the European Union
English (EN) (65.35 KB - PDF)